SEOUL, South Korea,
June 18, 2024 /PRNewswire/
-- GenKOre, a pioneer in gene editing technology with its
proprietary hypercompact CRISPR, known as TaRGET, is pleased to
announce a strategic collaboration with Revvity's Gene Delivery
franchise (formerly known as SIRION Biotech GmbH), a
specialist in viral vector-based gene delivery for gene and cell
therapy. This research collaboration aims to develop effective gene
therapy treatments for ocular disorders, specifically targeting
Leber Congenital Amaurosis 10 (LCA10) and Usher Syndrome Type 2A
(USH2A).
Innovative Approach to Ocular Gene-Editing Therapy
GenKOre will leverage its proprietary TaRGET platform (tiny
nuclease, augment RNA-based genome editing technology) to create in
vivo gene therapies for LCA10 and USH2A. Unlike the widely known
CRISPR-Cas9, the TaRGET platform allows the entire editing module
to be delivered using a single adeno-associated virus (AAV) vector,
offering a more efficient and streamlined approach to gene-editing
therapy.
Objectives of the Collaboration:
- Development of Superior Gene Therapies: Combining
GenKOre's TaRGET technology with Revvity's advanced AAV capsids to
develop in vivo gene-editing therapy with enhanced efficacy and
safety profiles.
- Expanding Therapeutic Applications: Validating the
applicability of the TaRGET platform for in vivo therapy and
extending its utility to a broader spectrum of rare diseases.
- Advancing Gene Editing Technology: Leveraging the
combined expertise of both companies to address unmet medical needs
and pioneer new frontiers in genomic medicine.
Leadership Comments
"This collaboration adds to our expanding toolbox of TaRGET
technologies in the important, emerging area of gene
therapeutics," said Yong-Sam
Kim, Founder and Co-CEO of GenKOre. "Leveraging our
expertise in gene editing technology and Revvity's capabilities in
AAV vector development will allow us to better address unmet
medical needs and open new frontiers for drug discovery in genomic
medicine."
"At Revvity, we seek to challenge the status quo to help
transform the future of human health. Gene therapies have the
potential to be curative and AAVs are enabling this as a versatile
technology to efficiently deliver genes to target cells. We're
excited to provide our AAV vector development technology and
expertise to support GenKOre's research in developing new gene
therapies for ocular diseases," said Bryan Kipp, SVP, Licensing and Technology,
Revvity.
If the strategic research collaboration is successful, GenKOre
has the opportunity to expand the agreement to a full development
and commercialization license.
About GenKOre
GenKOre has been devoted to developing powerful gene-editing
technology optimized for in vivo gene editing and recently signed a
collaboration and license agreement with a US-based biotech company
in a deal valued at approximately $550
million. The TaRGET platform includes TaRGET-cleavage,
TaRGET-base editing, TaRGET-gene regulation, and TaRGET-gene
correction system, all deliverable by an all-in-one AAV vector.
This technology is noted for its compactness, high efficiency,
persistency, specificity, and expandability. GenKOre is focused on
developing gene editing therapies for ocular, muscular, and
neurological diseases. The TaRGET (CRISPR-Cas12f) technology
features hypercompact Cas nucleases (1.7kb compared to Cas9's
4.1kb) and powerful engineered gRNAs, which, in complex, ensures
highly efficient and safe editing.
Revvity Gene Delivery
Revvity Gene Delivery is a business unit of Revvity, a global
leader in life sciences and diagnostics focused on developing novel
solutions for the world's greatest health challenges.
About Revvity
At Revvity, "impossible" is inspiration, and "can't be done" is
a call to action. Revvity provides health science solutions,
technologies, expertise and services that deliver complete
workflows from discovery to development, and diagnosis to cure.
Revvity is revolutionizing what's possible in healthcare, with
specialized focus areas in translational multi-omics technologies,
biomarker identification, imaging, prediction, screening, detection
and diagnosis, informatics and more.
With 2023 revenue of more than $2.7
billion and over 11,000 employees, Revvity serves customers
across pharmaceutical and biotech, diagnostic labs, academia and
governments. It is part of the S&P 500 index and has customers
in more than 190 countries.
info@genkore.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/genkore-announces-strategic-collaboration-with-revvity-to-develop-innovative-gene-therapy-treatments-302173587.html
SOURCE GenKOre